Sagimet Biosciences Inc. has announced the presentation of two posters at the American Association for the Study of Liver Disease (AASLD) - The Liver Meeting® 2025, held from November 7-11, 2025, in Washington, DC. The presentations detailed results from secondary analyses of the Phase 2b FASCINATE-2 clinical trial evaluating denifanstat in patients with metabolic dysfunction-associated steatohepatitis (MASH) and advanced fibrosis. One poster, presented by Dr. Rohit Loomba, reported that denifanstat treatment led to significant improvements in liver fibrosis, including a ≥2-stage improvement in fibrosis in F3 MASH patients and improved liver fibrosis and biomarkers in patients identified as qFibrosis stage 4 (qF4) by AI-based digital pathology. In the qF4 subgroup, 85% of denifanstat-treated patients experienced at least a 1-stage regression in fibrosis compared to 33% in the placebo group. A second poster, presented by Dr. Vlad Ratziu, used spatial computational histology to stratify responders to denifanstat based on baseline fibrosis features. The results from these analyses have already been presented at the 2025 AASLD meeting.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sagimet Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9572174-en) on November 10, 2025, and is solely responsible for the information contained therein.
Comments